One-for-One: Every Lost Exchange Patient Became an Uninsured One, and Our Upgrade Was Wrong

Results vs. Consensus

Q2 2026 Scorecard

Year-Over-Year Comparison

The 270bp improvement in salaries and benefits and the 450bp deterioration in other operating expenses are both largely artifacts of the Florida program: $1.372B of incremental revenue enlarges the denominator for every ratio, and $829M of the matching provider-tax expense sits in other operating expenses. The underlying cost read is management's own: same-facility cost per equivalent admission was essentially flat year over year.

The Florida Adjustment

No figure in the table above can be interpreted without this. The quarter includes incremental revenues of $1.372B and other operating expenses of $829M related to the Florida directed payment program, covering October 1, 2024 through June 30, 2026, following CMS approval during the quarter. Of those amounts, approximately $980M of revenue and $557M of expense relate to periods prior to 2026.

The 8-K also footnotes that Revenue per Equivalent Admission, Inpatient Revenue per Admission and Outpatient Revenues as a Percentage of Patient Revenues all include the Florida incremental revenues. The reported same-facility rate growth of 6.4% and inpatient revenue per admission growth of 15.4% are therefore not clean pricing reads and should not be compared with the 2.9% and 3.1% prints of the prior two quarters.

Assessment: Adjusting only for the prior-period portion, which is the conservative adjustment since the $120M relating to 2026 is genuinely this year's economics, the quarter's Adjusted EBITDA declined 6.4% year over year on revenue up 3.5%. That is the underlying picture, and it is materially worse than any headline in the release. Approximating the per-share effect at the quarter's 22.6% effective tax rate, the prior-period catch-up is worth roughly $1.47 of the $7.62 diluted EPS, which would put clean EPS near $6.15 against $6.83 a year ago. That approximation ignores any noncontrolling-interest allocation on the affected Florida facilities and is therefore an upper bound on the benefit.

Quarter-Over-Quarter Comparison

Ex the prior-period Florida catch-up, sequential Adjusted EBITDA of $3,604M is below Q1's $3,802M despite revenue growing, which is the cleanest single indictment of the quarter's underlying trajectory. The offsetting positive is real too: same-facility equivalent admissions accelerated 140bps to 2.7%, back inside the guided 2% to 3% range exactly as management committed on the Q1 call.

Revenue assessment. Strip the accounting and the operating picture is a company growing volume at 2.7% and losing rate to payer mix. Insured equivalent admissions excluding exchanges grew 3.2% in the quarter and 2.2% year to date, which is at or above the long-term algorithm. Medicare grew 3.6%, Medicaid 2.7% and commercial excluding exchanges 2.4%. Every insured category is healthy. The exchange book fell 15% and the uninsured book rose 15%, and because those two moved in near-lockstep the volume shows up while the revenue does not.

Margin assessment. This is the encouraging half of the quarter and it deserves to be said plainly: HCA held cost per equivalent admission flat year over year while absorbing a payer-mix shock, and improved it 1.4% sequentially. Same-facility professional fees moderated to 8.5% growth from 11% three quarters ago and were roughly flat sequentially. The resiliency program is doing what it was built to do. The problem is that it was sized to offset roughly $400M of a $600M to $900M exchange headwind, and the headwind is now $1.0B to $1.2B.

EPS assessment. Reported diluted EPS growth of 11.6% is the least informative number in the release. Between the prior-period Florida recognition and a share count down 7.9%, essentially none of it is operating progress. On a clean basis the quarter went backwards, and the six-month figures tell the same story: revenue up 6.5% to $39.339B, net income attributable up just 1.7% to $3.319B.

The Exchange Model: What Broke and What Did Not

This is the analytical core of the quarter and, for us, of the past four. The exchange headwind was never a single number. It is the product of three assumptions, and management has now published observed data against all three.

"the volume declines that we are seeing at first and second quarter on the exchanges, are 15% in both first and second quarter, are in line with our original guidance estimates in terms of exchange volume decline. Whit's different as we have gone through second quarter is that we originally assumed that about 80 to 85% of the patients who lose exchange coverage would become uninsured. And our data is telling us now that it is closer to 1-for-1. And so that is really the biggest driver of any of the updated estimate of the impact." — Michael A. Marks, CFO

Management offered three independent pieces of evidence for the one-for-one conclusion, which is more corroboration than these disclosures usually carry. Year-to-date same-facility exchange equivalent admissions are down roughly 22,000 while uninsured equivalent admissions are up roughly 26,500. Inpatient payer mix by class is almost identical year over year, with exchanges and self-pay combined landing exactly where they were. And the CEO placed the arithmetic in scale terms.

"those 20 some thousand patients, Mike, that you referenced, we took care of about 1.1 million people. And so the implications for the company are really hinging on those 22 thousand patients. It is what it is. We understand that. But you have got to appreciate the context here in the backdrop of 1.1 million adjusted admissions." — Samuel N. Hazen, CEO

Assessment: The distinction that matters for forecasting is that this is a rate problem, not a demand problem. HCA is treating the same patients; it is being paid less for a subset of them. That is why volume looks fine and earnings do not. It also means the headwind does not self-correct with a demand recovery, and it does not lap until the exchange population stabilizes at its new, smaller level. The 6.8% of equivalent admissions still on exchanges is the remaining exposure, down from roughly 8% of admissions a year ago.

Concentration: Three Divisions, Half the Damage

The impact is not evenly spread. Three of fifteen domestic divisions, Gulf Coast, North Florida and South Atlantic, account for roughly 50% of the company's total exchange impact, with composite exchange adjusted-admission declines management described as far steeper than the company average. In two of the three, total volume is actually higher than a year ago; it is the mix that deteriorated.

Assessment: Concentration cuts both ways. It means the problem is diagnosable and localized rather than systemic, and it means those three divisions have a large fixed cost base sized for a payer mix that no longer exists. HCA's diversification argument, which the CEO has leaned on in every quarter of our coverage, worked in reverse here: a 2% shift in patient mix produced a disproportionate P&L effect because it landed where the exposure was densest.

Volume, Pricing and Payer Mix

Reported vs. Same-Facility Operating Statistics

Assessment: Ignore the two rate rows, which the filing itself flags as Florida-inflated. The meaningful pattern is admissions up 2.5%, ER visits up 3.6%, and both surgical categories down. HCA is taking more patients through the lowest-margin door and fewer through the highest-margin one. Length of stay improving to 4.643 days extends a genuine multi-quarter operating win. The portfolio continues to shrink at the edges, with six fewer freestanding surgery centers year over year even as the company adds outpatient sites of care overall.

Payer Mix (same-facility equivalent admissions, YoY)

Every insured category accelerated sharply from Q1, which is consistent with management's claim that the Q1 weakness was respiratory and weather rather than demand. Medicare went from 1.9% to 3.6%, Medicaid from 0.3% to 2.7%, commercial ex-exchanges from 0.6% to 2.4%.

Assessment: The Q1 thesis that the volume shortfall was temporal has been vindicated completely, and that deserves acknowledgement. It is also, unfortunately, not the variable that determines 2026 earnings. The newly disclosed mix weights are the numbers to carry forward: uninsured is now a little over 10% of equivalent admissions and exchanges about 6.8%. The remaining exchange exposure is roughly 45% smaller than the roughly 8%-of-admissions figure disclosed in January, so the incremental attrition risk from here is correspondingly smaller than what has already been absorbed.

Surgical Volume: The Emerging Problem

The CEO gave the most useful decomposition of the call, splitting inpatient surgery into emergent and elective channels.

"The other piece of our inpatient surgery is clearly elective, which represents about a third. And we are down this year more than we were last year. Last year, we were down on elective 2%, This year, we are down on elective 6%. We do believe that HICS demand which is a big piece of our elective declines on both inpatient and outpatient is a part of it." — Samuel N. Hazen, CEO

The CEO named three contributing causes beyond exchange losses: physicians reporting that their activity flow is off, which they attribute to general affordability pressure in the economy; the Medicare inpatient rule change shifting some cases from inpatient to outpatient settings; and a competitive dynamic in the larger outpatient surgery market where HCA captures some migrating cases and loses others.

Assessment: The emergent channel holding at +2% for two consecutive years is the reassuring part and confirms the structural franchise is intact. The elective deterioration from -2% to -6% is the new concern, and the honest reading of management's answer is that they cannot fully separate exchange-driven loss from a broader consumer affordability effect. If a meaningful share is the latter, it will not recover when the exchange comparison laps, and it affects the profit pool that funds everything else. We are watching this more closely than the exchange line from here.

Key KPIs

Key Topics & Management Commentary

Overall Management Tone: Candid to the point of discomfort on the exchange miss, and confident to the point of insistence on demand and cost. Management opened with an unprompted acknowledgement that its own expectations proved directionally right but quantitatively wrong, published the specific assumptions that failed, and offered three independent corroborations of the revised conclusion. The weakest passages were on the elective surgery decline, where the explanation reached beyond exchanges into consumer affordability without being able to size either, and on the back-half bridge, where the guidance cut was larger than the disclosed assumption changes account for.

1. The Miss, Owned in the Opening Remarks

The CEO addressed the failed forecast in his first substantive paragraph rather than leaving it to Q&A, and framed it as an accuracy problem rather than a directional one.

"the enhanced premium tax credits expired at the end of the year, and the effects as expected were that many people became uninsured and still needed emergency care from hospitals. As we look at the first half of the year, our expectations proved accurate. Although the impact was greater than our estimates." — Samuel N. Hazen, CEO

Assessment: "Our expectations proved accurate although the impact was greater than our estimates" is a carefully constructed sentence, and it is defensible. HCA called the mechanism correctly two quarters before it happened and mis-sized two of the three parameters. That is a better record than most of the sell side managed. It does not change the fact that the mis-sizing is worth $350M at the midpoint and that the affected parameters are behavioural, which means the same uncertainty attaches to the revised estimate.

2. Why the Estimate Moved: Migration, Not Attrition

The single most important clarification of the quarter, because it determines whether the headwind is bounded by the size of the exchange book or by patient behaviour after they leave it.

Volume attrition was 15% in both quarters, squarely inside the original 15% to 20% assumption. What changed is that the assumed 15% to 20% of displaced patients who would find employer-sponsored coverage largely did not, and the assumed roughly 30% utilization decline for the newly uninsured did not occur. Both errors run the same way: more uninsured patients, using more care, than modelled.

Assessment: The revised $1.0B to $1.2B range now embeds a nearly worst-case behavioural assumption (essentially all displaced patients become uninsured, with no utilization relief), which paradoxically makes it more robust than the original. There is less room for the estimate to deteriorate further on the same parameters, because those parameters have effectively been taken to their limits. The residual risk shifts to whether attrition itself extends beyond 15% into 2027.

3. Florida Approved, and Mostly Backward-Looking

The catalyst we flagged as unguided upside in April arrived, and it is large: $543M of net benefit recognized in the quarter, of which $423M relates to periods before 2026.

"During the second quarter, the company recognized $400 million of incremental net benefit from Medicaid supplemental payment programs. This included a $540 million incremental net benefit related to the recently approved Florida program from October 1, 2024 to June 30, 2026. This benefit was partially offset by retro payments received in second quarter of 25." — Michael A. Marks, CFO

The full-year supplemental assumption swung from a $50M to $250M decline to a $300M to $500M benefit. But management was explicit that the arithmetic implies a headwind from here.

Assessment: We called Florida correctly and it still does not help the forward case much. Roughly 78% of the recognized benefit is a catch-up for periods already reported, which means it inflates 2026 optics and creates a 2027 comparison problem worth about $1.47 per share. The genuinely recurring piece, the $120M attributable to 2026 periods, is a modest ongoing positive. Management's own guidance implies the second half carries a $100M to $300M supplemental headwind as 2025's approvals and retro payments outrun the incremental Florida contribution.

4. Volume Delivered Exactly What Management Promised

On the Q1 call management committed to 2% to 3% volume growth over the remaining three quarters. Q2 delivered same-facility admissions up 2.5%, equivalent admissions up 2.7% and ER visits up 3.6%, with insured equivalent admissions excluding exchanges up 3.2%.

"Despite the payer mix shift, we were pleased with our volume growth. Insured volumes, excluding exchanges, across many of our services, were solid with improving trends over the course of the first 6 months. Emergency room visits, cardiac procedures, and rehab volumes help drive these improvements." — Samuel N. Hazen, CEO

Assessment: A promise made and kept in a single quarter, which is worth noting given how much of this coverage has turned on whether management's forward statements hold. The demand franchise is not the problem and has not been at any point in the past four quarters. This is why we resist the reading that HCA is a broken business; it is a well-run business absorbing a policy-driven repricing of roughly 2% of its patients.

5. Cost Control Is Working, and Is Not Enough

The resiliency program produced its best evidence yet. On management's own like-for-like measure, same-facility cost per equivalent admission considering supplemental programs was essentially flat year over year and improved 1.4% sequentially. Total cost per adjusted admission, combining salaries and benefits, supplies and other operating expenses, was flat to slightly up. Same-facility professional fees moderated to 8.5% growth from 11% three quarters ago.

"If we look at all of the work in flight with resiliency the gaining maturity of these programs, we are confident that we are gonna be able to bend the cost curve. And bend the cost curve, improve our cost trends, if you will, in the second half of the year and into 2027." — Michael A. Marks, CFO

Assessment: Holding unit cost flat through a demand mix shock is genuinely good execution and validates the pillar we have carried since initiation. The uncomfortable arithmetic is that the $400M resiliency program was sized against a $600M to $900M exchange headwind and now faces $1.0B to $1.2B. Cost control has gone from being the offset to being a partial offset. Management's commitment to bend the curve further into 2027 is the right ambition and, notably, the first time they have made a forward cost commitment beyond the current year.

6. Elective Surgery and the Affordability Question

The most analytically troubling disclosure, because management could not fully attribute it. Elective inpatient surgeries are down 6% year to date against down 2% in 2025, and outpatient surgeries, roughly 90% elective, fell 3.4%.

"We do hear from our physicians that their activity flow is off a little bit this year. They are attributing it as you would suspect to sort of the general affordability and pressures that people are experiencing with the economy as a whole. it is hard for us to tease that apart, but that is the best feedback loop that we have." — Samuel N. Hazen, CEO

Management's response is operational: investing in operating room equipment, optimizing throughput and flow, and aligning with physicians to strengthen network connection.

Assessment: An exchange-driven elective decline laps and recovers. A consumer-affordability-driven elective decline does not, and it would extend to the commercial book that is currently HCA's healthiest. Management explicitly cannot separate them. This is the item most likely to matter to 2027 and it is the one with the least data attached, which is an uncomfortable combination and a principal reason we are not staying constructive through the de-rating.

7. Capacity Investment Accelerates Into the Reset

HCA is spending through the downturn. More than $7B of approved capital comes online over the next three years, including 1,000 to 1,200 additional inpatient beds and a substantial outpatient build. Sites of care grew 5% year over year, roughly 250 facilities, with another 250 to 300 in the capital or acquisition pipeline, which would add roughly 10% more network capacity.

The CEO set the build in historical context: HCA has grown from roughly 37,000 beds in operation to about 42,000 today, an increase of roughly 15%, over a span beginning around 2018.

"Our occupancy level since that time has grown from 71% to 75%. So in addition to adding roughly 15% inpatient capacity to our company, our utilization of that capacity has grown by 5 points." — Samuel N. Hazen, CEO

The CEO also argued the demographic backdrop in HCA markets, naming Florida, Texas, Utah, Nevada, South Carolina, Georgia and Tennessee, is as favourable as during the pandemic-era migration.

Assessment: Adding capacity while occupancy is at 75% and volume is growing 2.7% is defensible, and the record of filling prior additions supports it. The risk is timing: $7B of capital lands over three years into an earnings base that has just been reset lower, and depreciation from it arrives regardless of whether the elective recovery does. Capital spending is guided unchanged at $5.0B to $5.5B, so this is a maintained commitment rather than an escalation.

8. The Guidance Cut Is Larger Than the Disclosed Assumptions Explain

Working the revisions: the exchange assumption worsened by $350M at the midpoint, the supplemental assumption improved by $550M, netting to a $200M improvement. The Adjusted EBITDA guidance midpoint fell $250M. That leaves roughly $450M of deterioration unaccounted for by the two named changes.

The 8-K commentary references "a service mix shift primarily related to a decline in surgical volume" as a contributing factor, and management repeated that framing on the call, but neither quantified it nor bridged the gap.

Assessment: This is the largest single question left open by the quarter. The most likely explanation is that the elective surgery decline is worth a substantial part of it, which would make surgical mix a roughly $400M-scale full-year issue rather than a rounding item. Management chose to characterise it qualitatively while quantifying everything else to the $50M, and that asymmetry is conspicuous in a release that was otherwise notably forthcoming.

9. Cash Conversion Reverses Hard

Operating cash flow of $2.335B is down 44.5% from $4.210B. Management attributes it to timing differences on Florida supplemental cash flows, where the revenue has been recognized but the cash has not yet arrived, and to the prior-year deferral of federal income tax payments into Q4 2025 which inflated the Q2 2025 comparison.

Assessment: Both explanations are legitimate and verifiable against prior disclosures. The Florida timing in particular is mechanical: recognizing $1.372B of revenue for periods going back to October 2024 creates a receivable, not cash. What it does mean is that first-half operating cash flow of $4.349B funded $3.635B of buyback and $2.350B of capex with the balance from the balance sheet, which is where the $3.2B increase in total debt since December comes from. Leverage remains in the lower half of the target range.

10. Medicaid Work Requirements Enter the 2027 Frame

A new policy item was introduced for the first time in our coverage. A proposed rule on Medicaid work requirements is under litigation, and management gave the exposure split.

"we believe work requirements will have, you know, an impact in non expansion states. I am sorry. Sorry. They will have an impact in expansion states. Way more than nonexpansion states because of, you know, this focus on working adult As a reminder, of all of our Medicaid revenues, about 40% of our Medicaid revenues are an expansion state, 60% are not." — Michael A. Marks, CFO

Assessment: A 40% exposure to the affected category is meaningful but not alarming, and litigation may delay or reshape implementation. The relevant point for the thesis is that this is the third distinct federal policy channel to hit HCA's payer mix in eighteen months, after the subsidy expiration and the supplemental payment programs. The company is demonstrably good at managing these, and an investor is nonetheless underwriting a stream of them.

11. The Medicaid Conversion Slowdown Narrows to Texas

The new risk we flagged in April has been scoped. The conversion slowdown now accounts for roughly 20% of uninsured volume growth, with the one-for-one exchange migration making up the other 80%, and management located it "mostly in Texas" with "a modest financial impact."

Assessment: A useful de-escalation. In April this was an unsized channel attributed speculatively to immigration concerns; it is now geographically bounded and characterised as modest. We are downgrading it in the scorecard accordingly. It remains worth tracking because the mechanism, patients declining to apply for coverage they qualify for, is not one HCA can fix operationally.

Guidance & Outlook

^*The supplemental assumption was revised once already, on April 24, to a decline of $50M to $250M. The +$550M midpoint improvement shown here is measured from that April revision, which is the relevant comparison.

Implied second-half shape. First-half Adjusted EBITDA of $7.829B against a full-year range of $15.400B to $16.100B implies $7.571B to $8.271B in the second half, a midpoint of $7.921B. That is only 1.2% above the first half despite the first half containing the entire $423M Florida prior-period catch-up. Excluding that, second-half Adjusted EBITDA needs to grow roughly 7% over a Florida-adjusted first half. Management expects the Q4 growth rate to exceed Q3's, on exchange timing (Q4 2025 exchange volume grew only 2.5%, an easier comparison), supplemental payment timing and the resiliency ramp.

Street at. Consensus had already reset to the July 14 preliminary figures, which the company then delivered exactly. Against post-preview marks, revenue beat by 2.4% and adjusted EPS by 0.4%. Against the pre-July-14 expectation set, the answer is the 6.9% single-session decline.

Guidance style. The pattern of the prior three quarters, embedding every headwind and excluding every unapproved upside, held until it did not. Florida converted and was worth $543M, exactly as the excluded-upside framing implied it could be. What changed this quarter is that management also had to re-cut a headwind assumption it had reaffirmed only three months earlier. Management now characterises the revised guidance as "more in line with our long term adjusted EBITDA growth rate target of 4% to 6%," which is a reset of the framing as well as the number.

Analyst Q&A Highlights

What Drove the Increase in the Exchange Headwind Estimate

The first question went directly to the revision and produced the clearest statement of what changed: volume attrition held, migration behaviour did not.

Q: "Hoping you can give us a little more color on your increased estimate for exchange headwinds. What were those key variables that were informing the $1 billion to $1.2 billion estimate, and what is giving you confidence in the magnitude of that increase. And then also by extension, kind of how we think about that directionally as it paces through the back half of the year?"
— Ben Hendrix, RBC Capital Markets

A: "we originally assumed that about 80 to 85% of the patients who lose exchange coverage would become uninsured. And our data is telling us now that it is closer to 1-for-1. And so that is really the biggest driver of any of the updated estimate of the impact... we began to see some slowing in exchange volume in the fourth quarter of 25... Our fourth quarter of 2025 exchange volume growth to prior year was only 2.5%. The full year 2025 versus 2024 was over 10%."
— Michael A. Marks, CFO

Assessment: The hindsight observation is the most useful part. Exchange volume growth decelerating to 2.5% in Q4 2025 from over 10% for the full year means the reforms began biting a quarter before the credits actually expired, which management attributes partly to the pausing of the low-income special enrollment period. Nobody, including us, read that Q4 deceleration correctly at the time; we attributed it entirely to the Medicaid redetermination comparison lapsing. It also gives Q4 2026 a genuinely easier comparison.

Whether the Surgical Decline Is Exchange-Driven or Something Broader

The most consequential exchange of the call for 2027, and the one where management's answer was least conclusive.

Q: "Your inpatient and outpatient surgeries were down. I wondered if you could go talk a little bit more about the types of surgeries that were impacted. Relative to service lines. Do you see this as being more elective procedures, postprumable procedures that are being, deferred and are you attributing this mainly to the HICS disenrollment"
— A.J. Rice, UBS

A: "Last year, we were down on elective 2%, This year, we are down on elective 6%. We do believe that HICS demand which is a big piece of our elective declines on both inpatient and outpatient is a part of it... We do hear from our physicians that their activity flow is off a little bit this year. They are attributing it as you would suspect to sort of the general affordability and pressures that people are experiencing with the economy as a whole."
— Samuel N. Hazen, CEO

Assessment: "A big piece of it, not the sole piece of it" is the operative phrase and it is unusually candid. Management is telling investors it cannot separate a policy effect that laps from a macro effect that may not. Given that elective surgery is the highest-contribution volume in the business and the deterioration tripled year over year, this is the item that should drive 2027 estimates and the one with the least visibility attached.

The Other Operating Expense Line and Forward Cost Trajectory

A question on the 450bp deterioration in other operating expenses drew the provider-tax explanation, the like-for-like cost measure, and a forward commitment on cost trends extending into 2027.

Q: "the other OpEx line was up a decent bit, and I am guessing some of that provider tax. But if you can just walk us through other moving pieces potentially there and pulling through a broader view because I am just curious how your thinking about the resiliency programs. Obviously, Hicks was a surprise. So any other incremental offsets that we can be thinking about maybe as we even think through 2027 and beyond?"
— Brian Tanquilut, Jefferies

A: "our other operating expenses are being inflated because of the provider tax associated with our way with the new provider tax for sure... When I look at that compared to prior year, we are only up about call it, flat to slightly up over prior year. That really reflects really good work in second quarter... professional fees. That are in other operating expenses. They are up about 8.5 percent on the same facility basis to the prior year, which is moderated and is pretty flat sequentially to first quarter."
— Michael A. Marks, CFO

Assessment: The questioner correctly diagnosed the provider tax before management confirmed it, which is the right instinct: a directed payment program funded by a provider tax grosses up both sides of the P&L. Professional fees moderating to 8.5% from 11% three quarters ago is real progress on the cost line we have flagged as structurally problematic since initiation, and is the first quarter in which that bear point has visibly improved.

Bridging Second-Half Guidance From Core Second-Quarter Earnings

An attempt to build the back-half bridge from a core Q2 base excluding both the supplemental programs and the exchange effect. Management answered with three qualitative drivers rather than an arithmetic bridge.

Q: "Looking at 2Q core EBITDA, excluding DPP and Hicks, can you help bridge us how you get to your guidance in the back half of the year specifically? Can you call out any changes to assumptions on the top line, like surgeries or paramedics? And on the bottom line, could you call it any savings, you know, like, initiatives that are coming online in details around those initiatives."
— Pito Chickering, Deutsche Bank

A: "I really think about 3 drivers that give us confidence here in our guidance for the back half of the year. The first 1 is really volume. And, you know, our second quarter results profile solid volume growth. Particularly in our insured population excluding exchanges... The second is our cost, and you noted that, but it is clear in the second quarter, we had really good performance in our cost trends."
— Michael A. Marks, CFO

Assessment: The question asked for an arithmetic bridge and received a qualitative one, with the third driver being the quality of the management team. Given that roughly $450M of the guidance cut is unexplained by the disclosed assumption changes, this was the moment to close that gap and it was not taken. The volume and cost points are both well evidenced; the absence of a numeric bridge is the notable part.

Where the Exchange Impact Is Concentrated

A question on the disclosure that three divisions carry half the impact produced the geography and an important nuance about volume versus mix.

Q: "You had mentioned that 3 divisions represented 50% of the impact Can you give some context in terms of either the geographies or just the commonalities in terms of the those divisions and why they are seeing a bigger impact?"
— Matthew Gillmor, KeyBanc

A: "We, we have 3 divisions. Our Gulf Coast division, North Florida, and South Atlantic division are the 3 that had a lot of HICS exposure, going into the year, and they have had dramatic impacts from the HICS exchange volume shift... In 2 of the 3 divisions, actually, we have more volume than we did in the previous year in total. But, again, the payer mix in those divisions had been compromised."
— Samuel N. Hazen, CEO

Assessment: Two of the three affected divisions grew total volume while their earnings deteriorated, which is the clearest possible illustration that this is a pricing event rather than a demand event. It also identifies where a recovery would have to come from, and those markets are in Texas and the Southeast, precisely the geographies management cites as demographically strongest.

Payer-Level Volume Detail and the One-for-One Arithmetic

A request for volume growth by payer produced the full breakdown plus the mix weights, and prompted management to lay out its corroborating evidence for the one-for-one conclusion.

Q: "can you guys also run the volume growth by payer and hopefully give us commercial employers separately from exchanges?"
— Justin Lake, Wolfe Research

A: "if I look at same facility equivalent admissions, second quarter of 26 compared to prior year, All in Medicare is up 3.6%. Medicaid is up 2.7%. Commercial, excluding the exchanges, are up 2.4%. The exchanges are down 15%, and the total uninsured is up 15%. I would note the total uninsured equivalent admissions now represents about 10 little over 10% of our total equivalent admissions and the exchanges now represent about 6.8% of our total equivalent admissions."
— Michael A. Marks, CFO

Assessment: The most valuable single answer of the call for modelling. Every insured category is growing at or above the long-term algorithm, and the newly disclosed mix weights bound the remaining exposure: with exchanges now 6.8% of equivalent admissions, the residual attrition risk is materially smaller than what has already been absorbed. This is the disclosure that argues against extrapolating 2026's damage into 2027 at the same rate.

Medicaid Work Requirements as a 2027 Risk

A forward-looking question introduced the next policy channel and drew the exposure split plus a candid note on the litigation overhang.

Q: "I just wanted to get an update on the internal views on work requirements for 2027. Just any thoughts on potential coverage leakage or headwinds or just general thoughts would be helpful."
— Whit Mayo, Leerink Partners

A: "of all of our Medicaid revenues, about 40% of our Medicaid revenues are an expansion state, 60% are not. We are monitoring this proposed rule as you can imagine. We are gonna have to see how it plays out. I mean, it is there are some litigation and legal challenges around the way that CMS is implementing the work requirements."
— Michael A. Marks, CFO

Assessment: Disclosing the expansion-state revenue split before being pressed is the kind of proactive quantification this management team has become better at over the four quarters we have covered. A 40% exposure with litigation pending is a watch item rather than a modelling input for now. It does reinforce that policy-driven payer-mix risk is a recurring feature of this business rather than a 2026 event.

What They're NOT Saying

1. What accounts for roughly $450M of the guidance cut. The disclosed assumption changes net to a $200M improvement while the Adjusted EBITDA midpoint fell $250M. A "service mix shift" was named and never sized, in a release that quantified everything else precisely.
2. How much of the elective surgery decline is affordability rather than exchange loss. Management said it is "hard for us to tease that apart." That split determines whether the 6% elective decline laps in 2027 or persists.
3. Any 2027 framing. No commentary on how the $423M prior-period Florida benefit, the annualized exchange headwind, or the elective softness combine next year. The only forward statement was a cost-curve commitment.
4. Whether exchange attrition extends beyond 15% in 2027. The revised estimate is a 2026 number. With 6.8% of equivalent admissions still on exchanges, whether that base stabilizes or continues eroding is unaddressed.
5. Cumulative progress against the $600M to $800M resiliency target. Fourth consecutive quarter unaddressed. Management now describes resiliency as a permanent multi-year program with 2027 benefits, without ever having reconciled the 2023 target.
6. The EHR migration. Second consecutive quarter with no mention, after being described in January as foundational and accelerating.
7. Whether the buyback pace is sustainable on this cash flow. First-half operating cash flow of $4.349B funded $3.635B of repurchase and $2.350B of capex, with total debt up $3.2B. Management repeated the intent to complete most of the authorization without addressing the funding mix.
8. Q3 versus Q4 magnitudes. Management said the Q4 growth rate may exceed Q3's but gave no sense of the gap, which matters because the full-year range is wide and second-half weighted.

Market Reaction

• The July 14 pre-announcement is the real event. HCA closed at $390.74 on July 13, opened at $354.35 on July 14 (a 9.3% gap down), traded $353.99 to $372.93, and closed at $363.60, down 6.9% or $27.14, on 4.2 million shares against a 1.7 million 30-day average (2.5x). The S&P 500 rose 0.4% that session.
• Pre-print setup for the July 24 release: HCA closed at $376.50 on July 23, having recovered 3.5% from the pre-announcement low close. The stock was down 19.4% year to date against the S&P 500 at +8.2%, up 10.3% over trailing twelve months and down 2.9% over the trailing thirty days. The 52-week closing range was $334.32 to $545.13.
• Reaction session (July 24, before-open reporter): Opened at $381.53, a 1.3% gap up, traded $376.48 to $399.00 (0.0% to +6.0%), and closed at $382.19, up 1.5% or $5.69. The S&P 500 was unchanged. Volume of 2.7 million against a 1.7 million average, or 1.6x.

Splitting the reaction across two sessions is the only way to read it correctly. The information content was delivered on July 14 and cost shareholders 6.9% in a session where the market was flat. The July 24 print added no new headline figures, every preliminary estimate having been delivered exactly, and the stock added 1.5% on the call detail.

The intraday pattern on July 24 is mildly encouraging: the stock traded as high as $399.00, up 6.0%, during the call before settling at $382.19. Something in the two hours of detail, most plausibly the payer-level volume breakdown showing every insured category growing 2.4% to 3.6% and the disclosure that exchanges are now only 6.8% of equivalent admissions, was read as bounding the remaining exposure. That it gave most of the gain back suggests the bounding was not enough to offset the unexplained portion of the guidance cut.

The broader context is a 19.4% year-to-date decline against an S&P 500 up 8.2%, a 28-point relative drawdown in seven months for a company whose volumes are growing at the top of its long-term range and whose unit costs are flat. That gap is the entire investment question.

Street Perspective

Debate: Is the Revised Exchange Estimate Finally Conservative?

Bull view: The revised $1.0B to $1.2B range embeds near-worst-case behavioural assumptions, essentially 100% migration to uninsured with no utilization relief. There is little room for the same parameters to deteriorate further because they have been taken to their limits. Volume attrition has held at 15% for two consecutive quarters, exchanges are now only 6.8% of equivalent admissions, and Q4 carries an easier comparison.

Bear view: This estimate has now been wrong once and revised worse by $350M three months after being reaffirmed. The company has no reliable point-of-service visibility into coverage status, so every figure is an estimate built on estimates. Attrition could extend beyond 15% into 2027 as grace periods and enrollment cycles work through.

Our take: The bulls have the better argument on the specific parameters and we would not model further deterioration on migration or utilization. The residual risk genuinely shifts to whether the 6.8% base erodes further. What the bears get right is the epistemics: we upgraded a quarter ago partly on the reliability of this same model, and it was revised worse within one quarter. Confidence intervals around company estimates in this business should be wider than we applied.

Debate: Does Flat Unit Cost Prove the Franchise or Merely Delay the Problem?

Bull view: Holding same-facility cost per equivalent admission flat year over year through a payer-mix shock, improving it 1.4% sequentially, and moderating professional fees from 11% to 8.5% growth is exceptional operating execution. Management has committed to bending the cost curve further into 2027, the first multi-year cost commitment of this coverage. Volume growth of 2.7% with unit costs flat is a powerful combination once the mix headwind laps.

Bear view: The $400M resiliency program was sized against a $600M to $900M headwind and now faces $1.0B to $1.2B. Cost control has been demoted from offset to partial offset. And roughly $450M of the guidance cut remains unexplained by disclosed assumptions, which suggests something in the cost or mix base deteriorated that management has not named.

Our take: The cost execution is real, verifiable and the most underrated element of the story. It is also, at present, insufficient. The honest formulation is that HCA is running a very good business into a policy headwind larger than its mitigation capacity, and the gap closes when the headwind laps rather than when the mitigation grows. That timing is 2027 at the earliest.

Debate: Is 12.9x a Value Opportunity or a Value Trap?

Bull view: The stock trades at 12.9x guided EPS after a 19.4% year-to-date decline, with volumes at the top of the long-term range, unit costs flat, $7.210B of buyback authorization outstanding, and a management team that has hit its volume commitments. The de-rating exceeds the earnings cut by a wide margin: guidance fell 2.3% at the EPS midpoint while the shares fell far more.

Bear view: 12.9x is on a number containing roughly $1.47 per share of non-recurring prior-period Florida recognition. On a clean basis the multiple is 13.6x and 2026 clean EPS of roughly $28.13 is below 2025's $28.21 adjusted, so this is a down year that laps into a harder 2027 comparison. Elective surgery is deteriorating for reasons management cannot fully attribute, and Medicaid work requirements are the next policy channel.

Our take: We land with the bears, having been on the other side one quarter ago. The multiple looks cheaper than it is, the 2027 setup carries a $1.47 headwind before anything operational happens, and the one variable that would change the picture, elective surgery, is deteriorating with an unattributed cause. A business this well run at 13.6x clean earnings is not expensive and is not obviously mispriced either. That is a Hold.

Model Update Needed

Valuation framework. At the July 24 close of $382.19, HCA trades at 12.9x the midpoint of revised 2026 diluted EPS guidance of $28.70 to $30.50, and at approximately 13.6x our clean estimate of $28.13 excluding the prior-period Florida recognition. Market value is roughly $85B on 222.828 million shares. For 2027 we start from the clean base rather than the reported one, add roughly 7% of share-count benefit and the resiliency contribution management has committed to, and subtract the annualization of an exchange headwind that builds through 2026, which lands us near $29 with a wide error band around the elective surgery trajectory. Applying 13x to 15x to that figure gives a fair value band of roughly $375 to $435, midpoint approximately $405, implying roughly +6% from the current price. We narrow the multiple range from the 15.5x to 17.5x we applied in January and April: a business with a structurally larger policy-driven headwind, an unexplained portion of a guidance cut, and softening elective demand warrants a lower multiple than one whose principal risk was believed to be bounded.

Thesis Scorecard Post-Earnings

Overall: Thesis bifurcated. The two operating pillars we downgraded to Neutral last quarter both confirm: volume returned to the top of the range exactly as management promised, and unit costs held flat through a mix shock. Everything policy-adjacent moved against us. Bear #1 escalated on a behavioural parameter we did not separately test, Bear #2 escalated in a way that flatters 2026 and burdens 2027, and Bear #4 is now worse than the flat-net-income case we forecast in January. A sixth bear point is added for the elective surgery decline, which is the item most likely to determine 2027.

Action: Downgrade to Hold. We were wrong to upgrade in April, and the error is instructive rather than merely unlucky: we treated a single observable variable, volume attrition, as validating a three-variable model, when the two unobservable variables were where the risk actually sat. Both subsequently broke. At $382.19 the stock is no longer expensive, and on a clean basis it is not obviously cheap either: 13.6x on 2026 earnings that are marginally below 2025's, heading into a 2027 that laps a $1.47 per share benefit. The business is well run, the volume franchise is intact, and the cost execution is better than we credited. We would return to Outperform on evidence that elective surgery has stabilized, or below roughly $350 where the clean multiple approaches 12x. Fair value band $375 to $435, midpoint approximately $405. The Q3 print in late October is the next checkpoint, and Q4 carries the easier exchange comparison management flagged.